Report overview
This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Treatment in Global, including the following market information:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Alcoholic Steatohepatitis (NASH) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Off-Label Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis (NASH) Treatment include Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc. and Zydus Cadila, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Type, 2021 (%)
Off-Label
Therapeutic
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
